Abstract
Abstract Allergic asthma is a type 2 immune-response-mediated chronic respiratory disease. Recent studies have shown that mast cell activation influences the development and aggravation of allergic asthma. Therefore, the development of mast cell-targeting pharmacotherapy is important for regulating allergic airway inflammation. We investigated the efficacy of hispidulin (HPD) – natural flavone – in a mast cell-mediated ovalbumin (OVA)-induced allergic airway inflammation model. HPD alleviated symptoms of allergic asthma, mast cell infiltration, and reduced the levels of eosinophil peroxidase, β-hexosaminidase, and type 2 cytokines (IL-4, IL-5 and IL-13) in the bronchoalveolar fluid (BALF) and the level of immunoglobulins in serum. Furthermore, we confirmed the efficacy of HPD through the evaluation of IgE-mediated allergic responses in a mast cell line. HPD treatment inhibited mast cell degranulation through inhibition of the FcεRⅠ signaling pathway, and suppressed the expression of inflammatory cytokines (TNF-α, IL-4, IL-6, and IL-13) through suppression of the NF-κB signaling pathway. In addition, the antioxidant effects of HPD in activated mast cells were identified through modulation of antioxidant enzymes (SOD, Catalase) and the Nrf2/HO signaling pathway. In conclusions, HPD is a potential therapeutic candidate for allergic airway inflammation of asthma and acts by suppressing mast cell activation and oxidative stress.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call